Keyphrases
Axicabtagene Ciloleucel
100%
Large B-cell Lymphoma
95%
Chimeric Antigen Receptor T Cells (CAR-T)
95%
Relapsed or Refractory
91%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
88%
Chimeric Antigen Receptor T-cell Therapy
75%
Cytokine Release Syndrome
42%
Cell Therapy
40%
Lymphoma
40%
Anti-CD19 chimeric Antigen Receptor T Cells
40%
Overall Survival
39%
Graft-versus-host Disease (GvHD)
35%
T Cells
33%
Standard of Care
32%
Myelodysplastic Syndrome
29%
Hematopoietic Cell Transplantation
26%
Acute Myeloid Leukemia
23%
Cell-to-cell
23%
Acute Lymphoblastic Leukemia
23%
Hematological Malignancies
22%
Overall Response Rate
22%
Complete Remission
21%
Cytarabine
21%
Multiple Myeloma
21%
Confidence Interval
21%
Diffuse Large B-cell Lymphoma (DLBCL)
20%
Chemotherapy
19%
Median Overall Survival
19%
Progression-free Survival
19%
Rituximab
18%
Mantle Cell Lymphoma
18%
Durable Response
17%
KTE-X19
16%
Blinatumomab
16%
Post-transplant Lymphoproliferative Disorder
16%
Granulocyte Colony-stimulating Factor (G-CSF)
16%
Marrow Transplantation
16%
Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS)
15%
Stem Cell Transplantation
15%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
15%
Retrospective Analysis
14%
Neurological Events
13%
Complete Response Rate
13%
American Society
13%
Initial Treatment
13%
Hematopoietic Stem Cell Transplantation
13%
Solid Organ Transplantation
13%
Lymphoma Patients
12%
Adverse Events
12%
Phase II Study
12%
Medicine and Dentistry
Axicabtagene Ciloleucel
98%
Large-Cell Lymphoma
89%
Chimeric Antigen Receptor T-Cell Immunotherapy
74%
Overall Survival
59%
Chimeric Antigen Receptor T-Cell
52%
Chimeric Antigen Receptor
47%
Cytokine Release Syndrome
44%
Cell Therapy
41%
Transplantation
40%
Hematopoietic Cell
39%
T Cell
37%
Acute Lymphoblastic Leukemia
37%
Cell Transplantation
33%
Acute B-Cell Lymphoblastic Leukemia
33%
Acute Myeloid Leukemia
29%
Diffuse Large B-Cell Lymphoma
28%
Stem Cell Transplant
28%
Progression Free Survival
27%
Neoplasm
26%
Adverse Event
25%
Diseases
24%
Multiple Myeloma
23%
Immunity
22%
Clinical Trial
20%
Arm
20%
Rituximab
20%
Infusion
19%
Biological Marker
18%
Hematologic Malignancy
18%
Mantle Cell Lymphoma
17%
Cancer
17%
Blinatumomab
16%
Event Free Survival
16%
Effector Cell
16%
Cytarabine
16%
Non-Hodgkin Lymphoma
16%
Stem Cell Therapy
15%
Myelodysplastic Syndrome
15%
Hematopoietic Stem Cell Transplantation
15%
Leukapheresis
15%
Graft Versus Host Reaction
14%
Bendamustine
14%
Chemoimmunotherapy
13%
Toxicity and Intoxication
13%
B Cell
12%
Malignant Neoplasm
12%
Minimal Residual Disease
12%
Infection
12%
Allogeneic Stem Cell Transplantation
12%
Autologous Stem Cell Transplantation
11%